» Articles » PMID: 26612984

Lipidomic and Metabolomic Characterization of a Genetically Modified Mouse Model of the Early Stages of Human Type 1 Diabetes Pathogenesis

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2015 Nov 28
PMID 26612984
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The early mechanisms regulating progression towards beta cell failure in type 1 diabetes (T1D) are poorly understood, but it is generally acknowledged that genetic and environmental components are involved. The metabolomic phenotype is sensitive to minor variations in both, and accordingly reflects changes that may lead to the development of T1D. We used two different extraction methods in combination with both liquid- and gas chromatographic techniques coupled to mass spectrometry to profile the metabolites in a transgenic non-diabetes prone C57BL/6 mouse expressing CD154 under the control of the rat insulin promoter (RIP) crossed into the immuno-deficient recombination-activating gene (RAG) knockout (-/-) C57BL/6 mouse, resembling the early stages of human T1D. We hypothesized that alterations in the metabolomic phenotype would characterize the early pathogenesis of T1D, thus metabolomic profiling could provide new insight to the development of T1D. Comparison of the metabolome of the RIP CD154 × RAG mice to RAG mice and C57BL/6 mice revealed alterations of >100 different lipids and metabolites in serum. Low lysophosphatidylcholine levels, accumulation of ceramides as well as methionine deficits were detected in the pre-type 1 diabetic mice. Additionally higher lysophosphatidylinositol levels and low phosphatidylglycerol levels where novel findings in the pre-type 1 diabetic mice. These observations suggest that metabolomic disturbances precede the onset of T1D.

Citing Articles

Issues and challenges in diabetic neuropathy management: A narrative review.

Ismail C World J Diabetes. 2023; 14(6):741-757.

PMID: 37383599 PMC: 10294062. DOI: 10.4239/wjd.v14.i6.741.


Serum Metabolomics Reveals a Potential Benefit of Methionine in Type 1 Diabetes Patients with Poor Glycemic Control and High Glycemic Variability.

Zhang L, Guo K, Tian Q, Ye J, Ding Z, Zhou Q Nutrients. 2023; 15(3).

PMID: 36771224 PMC: 9921163. DOI: 10.3390/nu15030518.


Optimized integration of metabolomics and lipidomics reveals brain region-specific changes of oxidative stress and neuroinflammation in type 1 diabetic mice with cognitive decline.

Xiong F, Gong K, Xu H, Tu Y, Lu J, Zhou Y J Adv Res. 2022; 43:233-245.

PMID: 36585111 PMC: 9811331. DOI: 10.1016/j.jare.2022.02.011.


Application of Metabolomics in Various Types of Diabetes.

Wu F, Liang P Diabetes Metab Syndr Obes. 2022; 15:2051-2059.

PMID: 35860310 PMC: 9289753. DOI: 10.2147/DMSO.S370158.


A Contemporary Insight of Metabolomics Approach for Type 1 Diabetes: Potential for Novel Diagnostic Targets.

Chai J, Sun Z, Xu J Diabetes Metab Syndr Obes. 2022; 15:1605-1625.

PMID: 35642181 PMC: 9148614. DOI: 10.2147/DMSO.S357007.


References
1.
Sysi-Aho M, Ermolov A, Gopalacharyulu P, Tripathi A, Seppanen-Laakso T, Maukonen J . Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol. 2011; 7(10):e1002257. PMC: 3203065. DOI: 10.1371/journal.pcbi.1002257. View

2.
Carneiro A, Iaciura B, Nohara L, Lopes C, Veas E, Mariano V . Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. PLoS One. 2013; 8(9):e76233. PMC: 3848743. DOI: 10.1371/journal.pone.0076233. View

3.
Grohmann U, Fallarino F, Silla S, Bianchi R, Belladonna M, Vacca C . CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol. 2000; 166(1):277-83. DOI: 10.4049/jimmunol.166.1.277. View

4.
Franconi F, Bennardini F, Mattana A, Miceli M, Ciuti M, Mian M . Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr. 1995; 61(5):1115-9. DOI: 10.1093/ajcn/61.4.1115. View

5.
Kabarowski J, Xu Y, Witte O . Lysophosphatidylcholine as a ligand for immunoregulation. Biochem Pharmacol. 2002; 64(2):161-7. DOI: 10.1016/s0006-2952(02)01179-6. View